Orphan Medicines Launch Excellence

Sustaining launch success as Orphan Medicines come of age

White Paper

March 21, 2019
Orphan Medicines Launch Excellence
Launching Orphan Medicines excellently will become even more important over the next 5 years. More patients with rare diseases have pharmacotherapies available, and there are a growing number of disease-focussed registries, increasing public and policy maker awareness, and significant R&D investment in pharmacotherapies and in digital technologies to support trials and treatment. A new frontier of challenge faces Orphan Medicines companies as the gap between Orphan Medicines and mainstream specialty products narrows. To understand how to succeed in launching an Orphan Medicine in the coming years, companies must learn from past launches and apply an Orphan Medicines-focused Launch Excellence framework for success.
Webinar Replay

Register and replay our webinar to find out how pharmaceutical companies can optimise all the activities needed to take orphan medicines from clinical development to commercialisation, including:

  • The three fundamental orphan medicine launch excellence challenges
  • The ways in which companies launching orphan medicines can learn from excellence in mainstream launches
  • The specific areas of focus that are crucial for orphan medicines launch excellence